Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Data from the RIGHT Choice study showed that ribociclib/ET yielded efficacy benefits for luminal B/HER2E breast cancer vs combination chemotherapy.

Palbociclib combination therapy elicited a progression-free survival of 44.3 months compared with the 29.1 months of SOC in HR+, HER2+ breast cancer.